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Abstract
Familial Dysautonomia (FD) is an autosomal recessive congenital neuropathy that results from abnormal development and
progressive degeneration of the sensory and autonomic nervous system. The mutation observed in almost all FD patients is
a point mutation at position 6 of intron 20 of the IKBKAP gene; this gene encodes the IkB kinase complex-associated protein
(IKAP). The mutation results in a tissue-specific splicing defect: Exon 20 is skipped, leading to reduced IKAP protein
expression. Here we show that phosphatidylserine (PS), an FDA-approved food supplement, increased IKAP mRNA levels in
cells derived from FD patients. Long-term treatment with PS led to a significant increase in IKAP protein levels in these cells.
A conjugate of PS and an omega-3 fatty acid also increased IKAP mRNA levels. Furthermore, PS treatment released FD cells
from cell cycle arrest and up-regulated a significant number of genes involved in cell cycle regulation. Our results suggest
that PS has potential for use as a therapeutic agent for FD. Understanding its mechanism of action may reveal the
mechanism underlying the FD disease.
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Introduction
Familial dysautonomia (FD) is an autosomal recessive congen-
ital neuropathy that occurs almost exclusively in the Ashkenazi
Jewish population with a carrier frequency between 1 in 27 to 1 in
32 [1,2]. Ashkenazi Jews of Polish descent have a higher carrier
frequency of 1 in 18 [3]. FD results from abnormal development
and progressive degeneration of the sensory and autonomic
nervous system. Patients are severely affected with a variety of
symptoms in most body systems. Among these symptoms are
gastrointestinal and cardiovascular dysfunction, vomiting crises,
abnormal sensitivity to pain and temperature, and recurrent
pneumonia. Despite recent advances in patient management,
about 50% of patients die before the age of 40 [4,5,6].
The gene associated with the disease was linked to chromosome
9q31 and identified as the IKBKAP gene. This gene encodes the
IkB kinase complex-associated protein (IKAP; for simplicity, IKAP
is used rather than IKBKAP to refer to the mRNA encoded by this
gene). The point mutation observed in almost all FD patients
(.99.5%) is a change from T to C at position 6 of the 59 splice site
(59ss) of intron 20 [7,8]. The mutation results in a shift from
constitutive inclusion to alternative splicing of exon 20 (Figure 1A).
The splicing defect in FD is tissue specific. Tissues from the brain
and nervous system express primarily mutant IKAP mRNA
(skipping of exon 20), while other tissues express both wild-type
and mutant mRNA in different ratios [4,9,10]. The skipped
isoform has a frameshift relative to the wild-type mRNA that
results in a premature stop codon, leading to considerably reduced
IKAP expression [9,10]. The mutant transcript is a potential
target for degradation by the nonsense mediated decay (NMD)
pathway [11]. In our system, treatment with cycloheximide, an
inhibitor of NMD, did not alter the level of the mutant transcript
(data not shown); however, this is not consistent with observations
from another study [12].
The IKAP protein is a 1332 amino acid, 150-kDa protein that is
highly conserved in eukaryotes [13,14]. The function of IKAP has
been a subject of much research but is still obscure. Based on
homology to a yeast protein, ELP1, and co-purification with
human Elongator [13], IKAP is thought to be a subunit of the
Elongator complex, which assists RNA polymerase II in
elongation of transcription in the nucleus [13,15,16]. There is
evidence that in the cytosol IKAP is involved in regulation of the c-
Jun N-terminal kinase (JNK) signaling pathway [14], tRNA
modification [17], exocytosis [18], cell adhesion, migration of cells
and reorganization of actin in the cytoskeleton [19,20]. IKAP may
also play a role in oligodendrocyte differentiation and/or myelin
formation [21] and in p53 activation [22]. IKAP is also crucial for
vascular and neural development during embryogenesis [23].
Based on our current knowledge of FD and what is known so far
about IKAP, we presume that the key for effective therapy of FD is
increasing the amount of the normal, functional IKAP protein. We
found that an FDA-approved food supplement, phosphatidylserine
(PS), increased the amount of wild-type IKAP mRNA in FD cell
lines. Further, long-term treatment of FD cells led to a significant
increase in the amount of IKAP protein. Untreated FD cells
accumulated at the G1 state with lower levels of cells in S and G2
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with elevation in expression of genes involved in cell cycle
regulation. Overall, our data indicate that PS has promise for
treatment of FD patients.
Results
To examine the effect of potential drugs on the splicing of the
IKAP mRNA we used three FD cell lines derived from three FD
patients (termed FDA, FDB and FDD). In addition, a cell line
derived from a parent of an FD patient, and therefore
heterozygous for the FD mutation, and four matched cell lines
derived from healthy individuals were used as controls. Analysis
of the splicing pattern of exon 20 was performed by RT-PCR
using primers to the endogenous IKAP mRNA. Figure 1B reveals
that exon 20 was constitutively spliced in the control cell lines
(lanes 1–4); 96% inclusion was observed in the heterozygous cells
(lane 5), and from 38% to 52% inclusion was observed in the
three FD cell lines (lanes 6–8). Figure 1B also demonstrates that
IKAP mRNA was either expressed at higher levels or was
considerably more stable in the control compared to the FD-
derived cell lines. The levels of the wild-type and mutant isoforms
were further quantified by real-time quantitative PCR (QPCR)
analysis (Figure 1C). FD cells expressed considerably lower
amounts of wild-type IKAP mRNA compared to control cells
(Figure 1C, left side). The heterozygous cell line expressed 2.5-
fold less wild-type IKAP mRNA than did control cells. FD cells,
FDA, FDB and FDD, expressed 5.7-, 7.2- and 3.8-fold less,
respectively, wild-type IKAP mRNA than did control cells. As
shown in Figure 1C, right side, the skipped IKAP isoform was
expressed at different levels in the FD cell lines compared to the
heterozygous cell line. No skipped isoform was detected in control
cells (data not shown).
In order to characterize the IKAP protein levels, a western blot
analysis was conducted (Figure 1D). The control cell lines and the
heterozygous cell line expressed the wild-type IKAP protein at the
expected size of 150 kDa at similar levels (1.2 less IKAP protein in
heterozygous cells). However, despite the presence of both wild-
type and mutant mRNA isoforms as shown by RT-PCR, in FD
cells only a very faint 150-kDa band was observed. Between 4 and
5 fold less IKAP protein was observed in FD cells than in control
cells. No product of the size expected for the truncated protein,
79 kDa, was detected, in agreement with previous reports [10,24].
FD is characterized by dysfunction of the autonomic and
sensory nervous system resulting from incomplete neuronal
development and progressive neuronal degeneration [1]. We
therefore sought substances that would affect neuronal function
and would be safe for immediate testing in FD patients. We first
examined two food supplements, one based on choline and one
based on serine. The choline-based substance had little effect on
the level of IKAP mRNA. However, the serine-based substance,
phosphatidylserine (produced by Enzymotec under the SharpNPSH
brand), significantly increased IKAP mRNA and IKAP protein
levels in cells derived from FD patients. PS, a nutritional
supplement, is a major component of every living cell, especially
neuronal cells [25], and slows cognitive degeneration in human
subjects [26,27,28]. We found that in FD cell lines PS significantly
raises IKAP mRNA and protein levels. PS, shown in Figure 2A, is
used worldwide and is considered by the FDA as a safe and lawful
dietary supplement. PS was added to FD cells at concentrations
ranging from 0–300 mg/ml. The cells were harvested and RNA
was extracted 24 and 48 hr following the addition of PS for each
cell line; IKAP mRNA was analyzed by RT-PCR analysis and
QPCR. The highest effect of PS on IKAP mRNA levels was
obtained at different time points for each cell line. After 24 hr of
treatment the best results were obtained for cell line FDA; we
observed about a 5-fold increase in the amount of wild-type IKAP
mRNA after treatment with 5, 10 or 100 mg/ml PS compared to
levels in FDA cells treated with the solvent only (Figure 2B). At
200 mg/ml PS, the increase was 1.5 fold, and at 300 mg/ml a 1.2-
fold increase in wild-type IKAP mRNA levels was observed. A
possible explanation for lower efficacy at higher PS concentration
is the toxicity of the solvent at high volumes, although the solvent
itself did not affect IKAP mRNA levels (data not shown). After
48 hr of treatment, best results were obtained for cell line FDB;
IKAP mRNA levels peaked at about 3-fold higher than levels in
untreated cells at 100 and 200 mg/ml PS (Figure 2C). PS did not
affect the ratio of the included to skipped mRNA isoforms but
rather elevated the total amount of both isoforms. In FDD cells,
PS had variable effects on IKAP mRNA (Figure S1). In the
heterozygous cell line, PS treatment induced a slight increase in
IKAP mRNA (data not shown). These results indicate that the
effect of PS on the level of IKAP mRNA differed among FD cell
lines.
In clinical studies, PS efficacy increased as treatment was
prolonged [26]. We thus examined the effect of PS on the level of
IKAP mRNA in FDB cells after 3, 7 and 14 days of treatment. The
level of IKAP mRNA was evaluated by QPCR (Figure 3A) and
RT-PCR (Figure 3B). As shown in Figure 3A, PS treatment
increased the level of IKAP mRNA by 1.5 fold at 3 days, 1.7 fold at
7 days, and 2.5 fold after 14 days compared to levels in untreated
cells. Proteins were harvested two weeks after the addition of the
supplement and IKAP levels were analyzed by western blot. The
addition of PS increased the amount of IKAP protein by 2.3 fold
in FD cells treated with PS relative to untreated FD cells
(Figure 3C). It should be noted that the antibody used in this
western blot (from BD Bioscience) can detect only the wild-type
IKAP protein. The antibody used in Figure 1D to detect the level
of IKAP protein in the different cell lines (from Santa Cruz
Biotechnolgy) can theoretically detect both the wild-type and
truncated IKAP protein.
In order to test whether expression of genes in addition to IKAP
was altered as a result of PS treatment, we performed a human
gene expression microarray analysis (Human Gene 1.0, Affyme-
trix) of cDNA samples from FDB cells treated with 100 mg/ml PS.
Using SAM (Significance Analysis of Microarrays) analysis, we
identified 877 genes with significantly different levels of expression
following PS treatment: 441 genes were up-regulated and 436
Figure 1. Expression of IKAP mRNA and protein in FD cells. (A) Schematic diagram illustrating the area in IKAP responsible for FD. The FD
mutation at position six of exon 20 splice donor site is shown by an arrow. In FD patients, two mRNA isoforms, one containing exon 20 and one
without, can be present. (B) RT-PCR analysis of IKAP mRNA. RNA was extracted from control, heterozygous and FD cells and the endogenous splicing
products were separated on a 2% agarose gel after RT-PCR reaction using primers to exon 19 and 21. Isoforms were quantified using ImageJ. GAPDH
was used as control for cDNA amounts. (C) QPCR analysis of the IKAP mRNA. Left side: Level of exon 20 inclusion isoform (wt). Relative quantity
represents normalization to control cells. Right side: Level of exon 20 skipped isoform (mut). Relative quantity represents normalization to
heterozygous (Htz) cells. All values were normalized to HPRT mRNA. QPCR experiments were amplified in triplicate; results shown are mean values 6
SD. (D) Analysis of IKAP protein levels. Western blotting of extracts from the indicated cell lines using an anti-IKAP antibody (Santa Cruz
Biotechnology, D-17). Band intensities were quantified using ImageJ.
doi:10.1371/journal.pone.0015884.g001
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the Supplementary Material. We confirmed the effect of PS on six
significantly up-regulated genes (YWHAH, TM4SF1, MYC,
DCTPP1, BLM and BRIP1) and four significantly down-regulated
genes (RCAN2, ROBO2, CYP7B1, and ITGB8) using QPCR
(Figure 4). All values were normalized to levels of LZIC, which
were unchanged by PS treatment. A gene ontology (GO)
enrichment analysis of these genes was performed using the
Database for Annotation, Visualization, and Integrated Discovery
(DAVID) [29]. A significant GO enrichment was observed for the
up-regulated genes coding for proteins involved in regulation of
the cell cycle and DNA metabolic processes (Table 1). Complete
tables are presented in Figure S3. As a group, the down-regulated
genes did not present highly significant GO enrichment; most of
them function in developmental processes (data not shown). Using
the Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways database in DAVID we also observed a significant
enrichment for genes involved in the signaling pathways for
pyrmidine and purine metabolism, as well as for genes known to
be involved in base excision repair (Table 2).
Due to the fact that a significant number of genes up-regulated
by PS treatment are involved in cell cycle regulation, we tested the
effect of PS on the cell cycle distribution of FD cells using
propidium iodide (PI) staining and flow cytometry. Cell cycle
analysis of untreated FD cells revealed that a significantly higher
fraction of the cells were in the G1 stage compared to control or
heterozygous cells (Figure 5A). A lower fraction of the FD cells
were in the S+G2 stages, 1.5-fold less than in the control cells,
indicating that a low number of FD cells are in the dividing state
(Figure 5B). Treatment of FD cells with PS significantly raised the
fraction of cells in S+G2 stages by 1.5 fold compared to untreated
FDA cells (Figure 5C) and 1.7 fold compared to untreated FDB
cells (Figure 5D). These results indicate that PS releases FD cells
from cell cycle arrest.
Figure 2. PS raises IKAP mRNA levels in FD cell lines. (A) Chemical structure of PS. (B) FDA cells or (C) FDB cells were treated with 0, 5, 10, 100,
200 and 300 mg/ml PS. RNA was extracted after 24 hr for FDA cell line and after 48 hr for FDB cell line. Left side: QPCR analysis of the level of exon 20
inclusion isoform (wt). Data were normalized to levels in untreated control cells. Right side: RT-PCR analysis of the splicing of the endogenous IKAP
mRNA in FD cells. All splicing products were separated on a 2% agarose gel after RT-PCR reaction using primers to exons 19 and 21. The PCR products
were eluted and sequenced. All experiments were repeated independently three times, and the results shown are representative of an average
experiment. QPCR experiments were amplified in triplicate; results shown are mean values 6 SD.
doi:10.1371/journal.pone.0015884.g002
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mRNA and protein present in FD cells, we obtained three additional
food supplements and tested their effect on splicing. The first is
produced under the name Sharp?PS GOLD4508P and is a
proprietary conjugate of PS and docosahexaenoic acid (DHA), an
omega-3 fatty acid. Sharp?PS GOLD resembles the functional form
of natural (brain) PS,increases DHA availability inthe brain, and acts
to increase cognitive abilities [30]. The second substance tested was
L-a-glycerophosphorylcholine (GPC), a dietary supplement reported
to improve mental performance that is marketed as SharpGPC 85F.
GPC serves as a precursor for reconstituting a nerve cell membrane
component. Clinical trials over the past two decades have
demonstrated that treatment of subjects with adult-onset dementia
disorders with GPC at 1,000–1,200 mg per day protects against
Figure 3. PS raises IKAP mRNA and protein levels following long-term treatment. PS was added to FDB cells at a concentration of 100 mg/
ml. Every two days the medium was replaced and fresh PS was added. RNA was extracted 3, 7 and 14 days following the initial addition of PS. All
experiments were repeated independently three times, and the results shown are representative of an average experiment. (A) QPCR analysis of the
level of exon 20 inclusion isoform (wt). Data were normalized to levels in untreated control cells harvested on the same day. QPCR experiments were
amplified in triplicate; results shown are mean values 6 SD. (B) RT-PCR analysis of the splicing of the endogenous IKAP in FDB cells. All splicing
products were separated on a 2% agarose gel after RT-PCR reaction using primers to exons 19 and 21. The PCR products were eluted and sequenced.
(C) Western blotting using an anti-IKAP antibody (BD-Bioscience) of FDB cells treated with PS for two weeks. The exposure of the analysis of 293T cells
was reduced to one fourth of its original amount in order to avoid intense background and to better visualize the effect of PS. Band intensities were
quantified using ImageJ.
doi:10.1371/journal.pone.0015884.g003
Figure 4. Validation of gene expression microarray analysis by QPCR. FDB cells were treated with 100 mg/ml PS. RNA was extracted 24 hr
following the addition of the supplement. A portion of each RNA sample was used for microarray analysis, and an aliquot was saved for experimental
validation. QPCR analysis of genes shown by the gene expression microarray analysis to be (A) up-regulated or (B) down-regulated as a result of PS
treatment. Each panel shows the levels in FDB cells after PS treatment relative to untreated FDB cells. (C) All values were normalized to a control, the
LZIC gene transcript, that did not change as a result of PS treatment. QPCR experiments were amplified in triplicate; results shown are mean values
6S.D.
doi:10.1371/journal.pone.0015884.g004
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Third, we tested Krill oil+4225F, a proprietary complex of marine-
derived DHA and eicosapentanoic acid (EPA), delivered as
triglycerides or attached to phospholipids. Krill oil+4224F also
contains a significant amount of astaxanthin. A similar combination
improves blood-lipid markers, including LDL, HDL and triglycer-
ides, and in clinical studies, Krill oil has greater potency than omega-
3, due to its unique structure and composition [32,33].
FD cell lines were treated with these three formulations, and the
effects on the splicing of IKAP mRNA were analyzed by RT-PCR
and QPCR (Figure 6). At 5 mg/ml, the Sharp?PS GOLD
supplement increased the level of IKAP mRNA level 4.2 fold
compared to levels in untreated cells (Figure 6A). Sharp?PS
GOLD increased the level of the wild-type IKAP mRNA at one
twentieth the effective concentration of PS. Treatment with GPC
did not significantly increase the amount of wild-type IKAP mRNA
Table 1. GO analysis for up-regulated genes.
Cluster 1 Enrichment score233.994
GO term p-value
1 # genes
2
Cell cycle 7.15E-41 96
Cell cycle phase 6.16E-36 69
Cell cycle process 2.08E-34 77
M phase 6.40E-34 61
Mitotic cell cycle 6.44E-30 60
Mitosis 4.02E-29 48
Nuclear division 4.02E-29 48
M phase of mitotic cell cycle 9.58E-29 48
Organelle fission 2.76E-28 48
Cell division 3.79E-24 49
Cluster 2 Enrichment score225.16
GO term p-value
1 # genes
2
DNA metabolic process 5.93E-35 74
Response to DNA damage stimulus 2.65E-21 51
DNA repair 5.25E-21 45
Cellular response to stress 1.89E-13 51
Cluster 3 Enrichment score222.12
GO term p-value
1 # genes
2
Nuclear lumen 3.65E-27 104
Intracellular organelle lumen 2.43E-22 108
Membrane-enclosed lumen 4.98E-22 110
Organelle lumen 1.60E-21 108
Nucleoplasm 1.44E-13 62
Nucleolus 1.05E-11 52
Cluster 4 Enrichment score221.08
GO term p-value
1 # genes
2
Chromosome 2.63E-31 65
Chromosomal part 7.37E-29 58
Chromosome, centromeric region 5.19E-18 29
Condensed chromosome 2.93E-15 27
Condensed chromosome, centromeric region 4.83E-15 21
Condensed chromosome kinetochore 6.45E-15 20
Condensed chromosome kinetochore 1.44E-13 21
Chromosome segregation 2.21E-12 21
Enriched categories were identified using DAVID to cluster differentially up- and down-regulated genes into functional categories using GO identification terms.
Significant GO enrichment (p-value ,0.05 after FDR multiple testing correction) was observed only for the up-regulated genes.
1FDR multiple testing correction.
2Number of identified genes in Gene Ontology (GO) category.
Enriched categories were identified using DAVID; See supplementary file 3 for complete tables.
doi:10.1371/journal.pone.0015884.t001
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type IKAP mRNA significantly (Figure 6C).
To evaluate PS with respect to other substances already tested
for FD treatment, we treated the FD cells with kinetin and
tocotrienol. Kinetin is a plant cytokinin, which was reported to
rescue mRNA splicing of IKAP ex vivo [12,24,34] and in patients
heterozygous for the FD mutation [35]. A significant increase in
wild-type IKAP mRNA levels and a shift towards a higher level of
exon 20 inclusion was observed with an optimal concentration of
100 mM of kinetin (Figure 7A), with no toxicity observed. In
contrast, tocotrienol, a member of the vitamin E family that was
reported to induce IKAP expression in FD cells [36,37,38], did not
affect IKAP mRNA expression in our system (Figure 7B); this
observation is similar to that of another publication [39]. These
results indicate that the FD cells used in this study are sensitive to
kinetin treatment but not to tocotrienol.
Discussion
FD is caused by a mutation in the IKBKAP gene that leads to
aberrant splicing. The skipped isoform produced from the mutant
gene is unable to produce normal IKAP protein, and the levels of
normal IKAP mRNA in FD patients fail to provide sufficient
amounts of IKAP protein. Subjects that are heterozygous for the
FD mutation express a lower level of wild-type IKAP mRNA than
do normal subjects (Figure 1B, 1C) but do not display any of the
clinical symptoms of FD [35]. We sought substances already
proven safe for clinical use that would increase the levels of wild-
type IKAP mRNA in cell lines created from cells taken from FD
patients in order to identify potential treatments.
We demonstrated that phosphatidylserine significantly in-
creased the levels of normal IKAP mRNA and protein. The
FDA has allowed two qualified health claims for the use of PS: PS
may improve the risk of cognitive dysfunction and may reduce the
risk of dementia in the elderly [27]. Use of PS derived from bovine
brain cortex has been shown to slow cognitive degeneration and in
some cases improve cognitive function, especially in adults
suffering from mild dementia [26,27,28]. The substance is also
effective in treating attention deficit hyperactivity disorder
(ADHD) in children [40]. Plant-derived PS was shown to be
effective for treatment of age-related cognitive decline in an open
trial study [41]. PS derived from soy lecithin is currently given
orally to adults at a dosage of 200–300 mg per day and to children
at 520 mg per day. The substance has been tested in humans and
animals at a higher dose than recommended for use in humans
with no toxicity observed [42,43,44,45]. The PS/DHA conjugate
(Sharp?PS GOLD) increased the level of IKAP mRNA at much
lower concentrations than the effective concentrations of PS in the
FD cells used in our study. This is probably due to the combined,
and possibly synergistic, effects of PS and DHA. This implies that
analogs of PS should be further investigated.
The effect of PS on IKAP levels was not related to changes in
the ratio between exon 20 inclusion and skipping. Rather PS acted
by increasing levels of transcription of this gene; increased levels of
mRNA led to elevation of the level of the normal IKAP protein. In
an attempt to elucidate the mechanism of action of PS, we
compared gene expression in FD cells in the presence and absence
of PS. A significant number of the genes up-regulated following PS
treatment are involved in cell cycle regulation. That FD cells have
improper regulation of the cell cycle was confirmed by examining
the cell cycle distribution of FD cells. Compared to control or
heterozygous cells, a lower percentage of FD cells were in growth
phases. A significant fraction of FD cells were in G1 compared to
control cells; this suggests that exit from G1 into the S phase is
impaired in FD cells. This may mean that the IKAP protein is
directly or indirectly involved in cell cycle checkpoint regulation,
and the reduced levels of IKAP in FD cells results in abnormal
growth of cells. PS treatment of FD cells elevated wild-type IKAP
mRNA and protein levels and resulted in a cell cycle distribution
similar to that of the control cells. A significant number of genes
up-regulated following PS treatment are also involved in DNA
metabolic processes and in DNA repair mechanisms. Upon
increases in cellular metabolism and synthesis of nucleotides,
transcription by RNA polymerase II increases. This enhancement
of RNA polymerase II activity results in a meaningful increase in
levels of mRNAs from genes that are usually under expressed, such
as IKAP in FD-derived cells. Increasing the expression level of
IKAP mRNA over a certain threshold leads to an increase in full-
length IKAP protein levels. Although the increase in transcription
level was not specific to the IKAP gene, its positive effect on the
level of IKAP is unquestionable. As PS has been proven safe, it
should be tested in FD patients.
The gene expression array analysis revealed that levels of
expression of a large number of genes were altered due to PS
treatment. It is not surprising that PS affects genes other than
IKAP, and these effects may be direct or indirect. Kinetin, for
example, was shown to affect splicing of other genes [24], and
many genes change their expression level in IKAP-deficient cells
[20,21,39]. Of particular interest in the list of genes demonstrated
Table 2. Signaling pathways enrichment of genes up-regulated by PS treatment.
Cluster 1 Enrichment score24.42
Term p-value
1 # genes
2
Pyrimidine metabolism 0.001268 13
Purine metabolism 0.03833 14
Cluster 2 Enrichment score24.05
Term p-value
1 # genes
2
Base excision repair 0.011218 8
Enriched signaling pathways were identified using the KEGG pathways database in DAVID to cluster up- and down-regulated genes. Significant KEGG enrichment (p-
value ,0.05 after FDR multiple testing correction) was observed only for the up-regulated genes.
1FDR multiple testing correction.
2Number of identified genes in the KEGG pathway category.
Enriched categories were identified using DAVID.
doi:10.1371/journal.pone.0015884.t002
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member, also known as L6-Ag, that influences cell motility
[46,47]. It is possible that the PS-induced increase in TM4SF1
mRNA levels increases IKAP levels through regulation involving
cell migration, which is impaired in Elongator-depleted cells [20].
Also of interest is the increase in MYC expression; this v-myc
myelocytomatosis viral oncogene homolog functions as a tran-
scription factor [48]. Since FD is characterized by defects in the
Elongator complex, involved in transcription elongation [13,15],
PS may affect IKAP levels through regulation of transcriptional
elongation.
Several gene expression profiling involving IKAP were
reported. Analysis of cerebrum samples of FD patients revealed
down regulation of genes involved in oligodendrocyte differenti-
ation and myelination compared to controls [21]. These genes do
not correlate with genes up-regulated after PS treatment. This is
probably because PS affects transcription rather than IKAP
function directly. It is also possible that these differences are
related to the type of cell tested (fibroblasts compared to
cerebrum). Also, gene expression analysis of HeLa cells treated
with RNAi directed against IKAP revealed that a significant
fraction of down-regulated genes encode proteins regulating cell
motility, cell proliferation, cellular processes such as autophagy,
metabolism and DNA repair; the up-regulated genes were
involved in metabolism, transcription and apoptosis [20]. PS
presumably does not influence IKAP directly; therefore, it is not
Figure 5. PS alters the cell cycle distribution of FD cells. One day prior to treatment 750,000 cells were seeded. The cells were treated with
100 mg/ml PS for 24 hr and then fixed and stained with PI according to the flow cytometry protocol. The percentage of cells (A) at the G1 stage and
(B) at the growth stages, S+G2, of untreated control, heterozygous, FDA and FDB cells. The percentages of cells at the growth stages, S+G2, of (C)
FDA or (D) FDB cells following PS treatment compared to untreated FD cells. All experiments were repeated independently four times, and the results
shown are mean values 6 SD. P-values of significant results are indicated.
doi:10.1371/journal.pone.0015884.g005
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treatment are different from genes affected by silencing of IKAP.
Microarray analysis performed on induced pluripotent stem cells
from FD patients compared to normal controls revealed that
down-regulated genes are involved in peripheral neurogenesis and
neuronal differentiation [39]. However, the fibroblast cells used in
this study were already differentiated, as are most of the cells in the
human body. The divergence of our altered genes due to PS
treatment from those reported in the literature in cells without
IKAP indicate the unique mechanism of action that results in the
PS-induced increase in IKAP levels. This body of data also
emphasizes the fact that IKAP is a multi-functional protein that
contributes to many processes in the cell.
Compounds that increase levels of correctly spliced transcripts
have been reported in studies of several disorders that result from
exon skipping. Most examples are found in experiments involving
models of the neuromuscular disorder spinal muscular atrophy
(SMA). Valproic acid [49], sodium butyrate [50], hydroxyurea
[51], aclarubicin [52], benzamide M344 [53] and a tetracycline-
like compound [54] have all been shown to promote inclusion of
exon 7 in the SMN2 transcript. For FD, several drugs, including
kinetin and tocotrienol, increase the levels of wild-type IKAP
mRNA and protein. In our system, kinetin significantly elevated
the level of the normal IKAP isoform. It also altered the ratio
between the included and the skipped isoforms, shifting the ratio
toward inclusion. Kinetin is a plant hormone from the cytokinin
family that promotes cell division [55]. It is used in the cosmetic
industry as an anti-oxidant with anti-ageing effects [56]. However,
kinetin has cytotoxic activity [57], especially at high concentrations
[58]. Additionally, in an in vivo study treating carriers of FD with
kinetin, some adverse effects resulted from treatment [35].
Therefore, kinetin has potential, but its toxicity must be further
assessed. Tocotrienols are members of the vitamin E family
considered to have neuroprotective and antioxidant properties
[59]. The toxicity levels for humans are presently unknown,
although estimates have been made based on studies in rats [60].
Tocotrienol, however, did not have an effect in our FD systems
(Figure 7B) or in another study [39]. Our data suggest that PS, a
Figure 6. Other supplements also increase IKAP mRNA levels in an FD cell line. (A) Sharp?PS GOLD4508P (Gold), (B) SharpGPC 85F (GPC), or
(C) Krill oil+4225F (Krill oil) were added to FDB cells at the indicated concentrations. RNA was extracted 24 hr following the addition of the
supplement. Left side: QPCR analysis of the level of exon 20 inclusion isoform (wt). Data were normalized to that of untreated control cells. Right side:
RT-PCR analysis of the splicing of IKAP in FDB cells. All splicing products were separated on a 2% agarose gel after RT-PCR reaction using primers to
exons 19 and 21. The PCR products were eluted and sequenced. All experiments were repeated independently three times, and the results shown are
representative of an average experiment. QPCR experiments were amplified in triplicate; results shown are mean values 6 SD.
doi:10.1371/journal.pone.0015884.g006
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Materials and Methods
Cell culture and treatment
Control fibroblast cell lines were kindly provided by Prof. Aharon
Razin from the Hebrew University Medical School in Jerusalem.
FDA and FDB cell lines, as well as the heterozygous cell line, were
obtained from the NIGMS Human Genetic Mutant Cell Repository:
FDA cell line is the GM00850, FDB is GM02342 and the
heterozygous cell line is GM04664 (purchased by Prof. Aharon
Razin). The FDD cell line was received from Channa Maayan. All
celllineswereimmortalizedbyIdaVigandYanivLerenthalfromTel
Aviv University by transducing the cells with a retroviral vector
expressing the catalytic subunit of human telomerase (hTERT), as
described previously [61]. HEK 293T cells were obtained from the
American Type Culture Collection (CRL-11268). 293T and control
fibroblast cell lines were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) with 10% fetal calf serum (FCS), 0.29 mg ml
–1 L-
glutamine, 100 U ml
–1 penicillin and 0.1 mg ml
–1 streptomycin at
37uC in a humidified atmosphere with 5% CO2. Heterozygous and
FD cell lines were cultured in medium containing 20% FCS. Cells
were seeded in 6-well or 10-cm plates one day prior to treatment and
were ,80% confluent at the time of treatment.
For the long-term treatment, the cells were seeded and on the
next day 100 mg/ml PS was added. Every two days the medium
was replaced and fresh PS was added. One week after the initial
PS treatment, the cells were split to allow proper growth. The PS
treatment was continued for an additional week. mRNA samples
were taken 3, 7 and 14 days from the initial treatment.
PS (soy lecithin derived, produced under the name Sharp PS)
and Sharp PS GOLD were obtained from Enzymotec (http://
www.sharp-ps.com/products/ps/ps.html) as powders. According
to the company’s recommendations, the powders were dissolved in
95:5 chloroform/methanol and a stock solution was made at
20 mg/ml. Sharp GPC was obtained from Enzymotec as a viscous
liquid and diluted in water. Krill oil was obtained from Enzymotec
as a viscous liquid and diluted in corn oil. Kinetin solution was
purchased from Sigma. Tocotreinol, full spectrum E with
tocotrienols, was produced by Swanson Ultra.
Semi-quantitative RT-PCR and QPCR analysis of IKAP
transcripts
After the indicated time, total RNA was extracted from treated and
untreated samples using TRI reagent (Sigma). RNA concentrations
were determined using a NanoDrop ND-1000 spectrophotometer. For
RT-PCR, 2 mg of total RNA were amplified using avian myeloblastosis
virus reverse transcriptase (RT-AMV,R o c h e )w i t ha no l i g o ( d T )r e v e r s e
primer. Products were amplified with Red Load Taq master mix
(Larova) using primers for exon 19 (forward, 59-CATTACAG-
GCCGGCCTGAGCAGCA-39) and exon 21 (reverse, 59-CT-
TAGGGTTATGATCATAAATCAGATT-39)o fIKAP. The splicing
products were separated on 2% agarose gels and were sequenced.
Alternative splicing isoforms were quantified using ImageJ.
Figure 7. The effect of substances already tested in FD models or patients on IKAP mRNA levels. (A) Kinetin or (B) tocotrienol (Toco) were
added to FDB cells at the indicated concentrations. RNA was extracted 24 hr following the addition of the substance. Left side: QPCR analysis of the
level of exon 20 inclusion isoform (wt). Data were normalized to that of untreated control cells. Right side: RT-PCR analysis of the splicing of the
endogenous IKAP. All splicing products were separated on a 2% agarose gel after RT-PCR reaction using primers to exons 19 and 21. The PCR
products were eluted and sequenced. All experiments were repeated independently three times, and the results shown are representative of an
average experiment. QPCR experiments were amplified in triplicate; results shown are mean values 6 SD.
doi:10.1371/journal.pone.0015884.g007
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using the Absolute Blue QPCR SYBR Green ROX mix (Thermo
Scientific). Primers used to detect the IKAP wild-type isoform
(inclusion of exon 20) were exon19F (59-TTCACGGATTGTCA-
CTGTTGTGCC-39)a n de x o n 2 0 R( 5 9-TTGTCCAACCACTT-
CCGAATCTG-39). For normalization HPRT mRNA was amplified
using HPRT-F (59-TGACACTGGCAAAACAATGCA-39)a n d
HPRT-R (59-GGTCCTTTTCACCAGCAAGCT-39)a su s e di n
[24]. Detection of the IKAP mutant isoform (skipping of exon 20) was
performed using primersbridge 19-21F (59-CACAAAGCTTGTAT-
TACAGACTT-39) and exon21R (59-CTTAGGGTTATGATCA-
TAAATCAG-39). Analysis was performed using the MxPro 4.01
software. All primer pairs yielded a linear standard curve with an
R
2.0.985 and efficiency of reaction between 90–105%. Data was
normalized to untreated cells. All experiments were repeated at least
three times, and QPCR experiments were performed in triplicate.
Western blot analysis
Total proteins were extracted from the cells using a hypotonic lysis
buffer (50 mM Tris-HCl, pH 7.5, 1% NP40, 150 mM NaCl, 0.1%
SDS, 0.5% deoxycholic acid, 1 mM EDTA) containing protease
inhibitor and phosphatase inhibitor cocktails I and II (Sigma). After
20 min centrifugation at 14,000 g at 4uC, the supernatant was
collected and protein concentrations were measured using BioRad
Protein Assay (BioRad). Proteins were separated in an 8% SDS-
P A G Ea n dt h e ne l e c t r o b l o t t e do n t oaProtran nitrocellulose transfer
membrane(Schleicher&Schuell).Themembraneswereprobedwith
eitheragoatanti-IKAPantibody(D-17,SantaCruz)oramouseanti-
IKAP antibody (BD Biosciences) for 12 hr at 4uC, followed by
incubation with secondary antibody, donkey anti-goat IgG HRP
(Santa Cruz) or goat anti-mouse IgG (Jackson), as appropriate.
Immunoblots were visualized by enhanced chemiluminescence
(SuperSignal West Pico chemiluminescent substrate; Thermo
scientific) and exposure to X-ray film.
Microarray analysis
Six Human Gene 1.0 microarray chips (Affymetrix) were used:
Three chips were used for the analysis of cDNA prepared from
FDB cells treated with PS, and three chips were used for the
analysis of cDNA prepared from FDB cells treated with the solvent
only (used as controls). Cells were treated with 100 mg/ml PS.
RNA was extracted 24 hr later using a Qiagen RNeasy Plus mini
kit, according to the manufacturer’s protocol. cDNA and
microarray chips were prepared and hybridized by the Bioinfor-
matics Unit of Tel Aviv University. One chip from each assay was
omitted from the analysis because of unsatisfying clustering results.
Analysis of microarray results was done using SAM. The results
were validated using QPCR. Primers for microarray QPCR
validation are presented in Figure S4. Enrichment analysis of these
genes was done using DAVID to cluster differentially up and
down-regulated genes into functional categories using GO
identification terms, as well as enrichment in signaling pathways
using the KEGG pathways database.
Flow cytometry
Cells were trypsinized, collected in PBS and centrifuged for
10 min at 282 g at 4uC. The cells were then fixed by dropwise
addition of the cell suspension into an ice-cold 70% ethanol in PBS
with gentle vortexing, and kept overnight at 220uC. Next, the
cells were washed with PBS, left for 30 min at 4uC and then
suspended in PBS containing 5 mg/ml DNase-free RNase and
stained with PI. Sorting was carried out using FACSort flow
cytometry (Becton Dickinson) at 10,000 events per sample. Cell
cycle analysis was performed with the ModFit software.
Supporting Information
Figure S1 PS effect on IKAP mRNA levels in FDD cell
line. FDD cells were treated with 0, 5, 10, 100, 200 and 300 mg/ml
PS. RNA was extracted after 24 hr (A) and 48 hr (B). Left side:
QPCR analysis of the level of exon 20 inclusion isoform (wt). Data
were normalized to levels in untreated control cells. Right side: RT-
PCR analysis of the splicing of the endogenous IKAP mRNA in FD
cells. All splicing products were separated on a 2% agarose gel after
RT-PCR reaction using primers to exons 19 and 21. The PCR
products wereeluted and sequenced. All experiments were repeated
independently three times, and the results shown are representative
of an average experiment. QPCR experiments were amplified in
triplicate; results shown are mean values 6 SD.
(TIF)
Figure S2 Genes up- and down-regulated after PS
treatment in FD cells. Gene expression microarray analysis
was performed on cDNA samples from FDB cells treated with PS;
data were compared to that from FDB cells treated with the solvent
only. All 441 up-regulated genes and 436 down-regulated genes
identified by significant analysis of microarray (SAM) are listed.
(DOC)
Figure S3 Complete Gene Ontology enrichment for up-
regulated genes. Continued from Table 1. GO analysis for up-
regulated genes revealed by microarray analysis following PS
treatment of FDB cells. Enriched categories were identified using
DAVID to cluster differentially genes into functional categories
using GO identification terms. Significant GO enrichment (p-
value ,0.05 after FDR multiple testing correction) was observed
only for the up-regulated genes.
(DOC)
Figure S4 Primers used for validation of microarray
results. Primers forward and reverse used for validation by
QPCR of 11 genes from the microarray analysis.
(DOC)
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